This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.20% per year. These returns cover a period from January 1, 1988 through April 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Bull of the Day: CRISPR Therapeutics (CRSP)
by Kevin Cook
FDA approval for revolutionary Sickle Cell Disease gene-editing treatment promises a bright future
CRISPR Therapeutics AG (CRSP) Up 20.5% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
CRISPR Therapeutics AG (CRSP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Wall Street Analysts Think CRISPR Therapeutics AG (CRSP) Could Surge 27.15%: Read This Before Placing a Bet
by Zacks Equity Research
The consensus price target hints at a 27.2% upside potential for CRISPR Therapeutics AG (CRSP). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
CRISPR (CRSP) to Focus on Next-Generation CAR T Pipeline
by Zacks Equity Research
Based on early data from ongoing clinical studies, CRISPR (CRSP) has decided to focus on the development of its next-generation CAR T pipeline and discontinue its first-generation CAR T candidates.
5 Best Performing Stocks of the Top ETF of November
by Sweta Killa
ARK Innovation ETF (ARKK), which provides thematic multi-cap exposure to innovation across sectors, has gained 35.2%, becoming the best-performing ETF of November.
Here's Why CRISPR Therapeutics AG (CRSP) is a Great Momentum Stock to Buy
by Zacks Equity Research
Does CRISPR Therapeutics AG (CRSP) have what it takes to be a top stock pick for momentum investors? Let's find out.
CRISPR (CRSP) Rises More Than 40% in Past 3 Months: Here's Why
by Zacks Equity Research
CRISPR (CRSP) expects a potential approval for its gene-edited therapy, Casgevy (exa-cel) in the United States for treating two debilitating blood disorders. The drug has been recently approved in the United Kingdom.
Vertex (VRTX) Gets EU Nod for Kaftrio Use in 2-5 Year Kids
by Zacks Equity Research
The European Commission approves Vertex's (VRTX) Kaftrio for expanded use to treat children aged two to five years with cystic fibrosis.
Zacks Industry Outlook Highlights Gilead Sciences, CRISPR Therapeutics, ACADIA Pharmaceuticals, Dynavax and Ligand Pharmaceuticals
by Zacks Equity Research
Gilead Sciences, CRISPR Therapeutics, ACADIA Pharmaceuticals, Dynavax and Ligand Pharmaceuticals are part of the Zacks Industry Outlook article.
5 Biotech Stocks Likely to Thrive as Industry Prospects Look Bright
by Ekta Bagri
New drug approvals and pipeline progress are likely to help maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position GILD, CRSP, ACAD, DVAX and LGND well amid volatility.
Vertex (VRTX) Non-Cystic Fibrosis Pipeline Boosts Stock This Year
by Zacks Equity Research
Vertex Pharmaceuticals (VRTX) is likely to achieve multiple clinical milestones in late/2023 and 2024, both in its CF and non-CF portfolio.
Wall Street Analysts Believe CRISPR Therapeutics AG (CRSP) Could Rally 33.75%: Here's is How to Trade
by Zacks Equity Research
The mean of analysts' price targets for CRISPR Therapeutics AG (CRSP) points to a 33.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
The Zacks Analyst Blog Highlights Arcellx, Bristol Myers Squibb, Solid Biosciences, Vertex Pharmaceuticals and CRISPR Therapeutics
by Zacks Equity Research
Arcellx, Bristol Myers Squibb, Solid Biosciences, Vertex Pharmaceuticals and CRISPR Therapeutics are included in this Analyst Blog.
CRISPR (CRSP), Vertex Get UK Nod for First Gene Therapy Casgevy
by Zacks Equity Research
CRISPR (CRSP) and Vertex's Casgevy, the first-ever gene-edited therapy, to treat sickle cell disease and transfusion-dependent beta thalassemia gets MHRA nod. Stock rises in pre-market trading.
Biotech Stock Roundup: BMY's Drug Approval, VRTX & CRSP Gene Therapy Get MHRA Nod
by Zacks Equity Research
Bristol Myers (BMY) and Vertex (VRTX) drug approvals are in focus in the biotech sector.
Company News for Nov 8, 2023
by Zacks Equity Research
Companies in The News Are: EMR,DHI,CRSP,ATSG
CRISPR Therapeutics (CRSP) Q3 Loss Narrower Than Expected
by Zacks Equity Research
CRISPR Therapeutics (CRSP) beats the mark for earnings and misses the same for sales in the third quarter.
CRISPR Therapeutics AG (CRSP) Recently Broke Out Above the 200-Day Moving Average
by Zacks Equity Research
When a stock breaks out above the 200-day simple moving average, good things could be on the horizon. How should investors react?
Vertex (VRTX) Q3 Earnings Beat, Sales Miss, Raises '23 View
by Zacks Equity Research
Vertex's (VRTX) third-quarter results reflect a year-over-year increase in revenues. The company raises its net product sales guidance for 2023.
Is Connect Biopharma Holdings (CNTB) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Connect Biopharma Holdings Limited Sponsored ADR (CNTB) and CRISPR Therapeutics AG (CRSP) have performed compared to their sector so far this year.
CRISPR Therapeutics AG (CRSP) Recently Broke Out Above the 50-Day Moving Average
by Zacks Equity Research
Is it a good or bad thing when a stock surpasses resistance at the 50-day simple moving average?
Wall Street Analysts See a 108.46% Upside in CRISPR Therapeutics AG (CRSP): Can the Stock Really Move This High?
by Zacks Equity Research
The mean of analysts' price targets for CRISPR Therapeutics AG (CRSP) points to a 108.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
CRISPR Therapeutics AG (CRSP) Crossed Above the 20-Day Moving Average: What That Means for Investors
by Zacks Equity Research
When a stock breaks out above the 20-day simple moving average, good things could be on the horizon. How should investors react?
CRISPR Therapeutics AG (CRSP) Surges 12.4%: Is This an Indication of Further Gains?
by Zacks Equity Research
CRISPR Therapeutics AG (CRSP) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Amicus Therapeutics (FOLD) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Amicus Therapeutics (FOLD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.